OR-NIKE
5.2.2020 20:02:11 CET | Business Wire | Press release
Today, NIKE, Inc. (NYSE: NKE), unveiled breakthrough innovation for athletes competing in the Tokyo 2020 Games, including footwear designed to provide runners with a measurable performance benefit for a new era of competition. The NEXT% platform, introduced by barrier-breaking marathoner Eliud Kipchoge, will now expand into new disciplines following its unparalleled success in distance running.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005708/en/
Ahead of the hottest Games on record, Nike also debuted progressive new collections featuring sustainable materials for all athletes. As the growing climate emergency continues to disrupt competition and training, Nike’s sustainable innovations signal the brand’s commitment to helping protect the future of the planet – and, consequently, the future of sport. Highlights include our most sustainably designed medal stand uniform in Team USA history, footwear built predominantly from recycled waste and lifestyle apparel that embraces the goal of a zero-carbon future.
“At Nike, we see sport’s greatest stage as our biggest opportunity to show the world what’s possible,” said NIKE, Inc. President and CEO John Donahoe. “After all, what’s at stake isn’t just records, but the future of sport itself. In Tokyo, we’ll help the world’s best reach new levels of performance with our revolutionary platform, while sharing real solutions for the barriers all athletes face under rapidly changing climate conditions.”
- Team USA Medal Stand Collection [link ] : This summer, Team USA will prove the power of sustainability during medal ceremonies. In Tokyo, U.S. medalists will take the podium in iconic Windrunner jackets reengineered with 100% recycled polyester, pants featuring 100% recycled nylon and recycled-rubber Nike Grind trim and the Nike Air VaporMax 2020, constructed with recycled manufacturing material and precision-knit uppers for minimal waste.
- Nike Air Zoom Alphafly NEXT% [link ] : Call it the ultimate test run: when Eliud Kipchoge broke the two-hour marathon barrier in Vienna this past October, he was wearing a prototype of the Nike Air Zoom Alphafly NEXT%. In Summer 2020, Nike’s newest race-day shoe makes its official debut with two new Nike Air Zoom pods, additional foam, an updated carbon fiber plate and an ultra-breathable upper – all adding up to improved cushioning and running economy.
- Nike Air Zoom BB NXT [link ]: Nike Basketball's new Air Zoom BB NXT is engineered to be as light and responsive as possible. With a new Nike Air Zoom pod system, exposed Nike React foam and a thin plate positioned above the foam, the shoe provides athletes with lightweight strength, optimized impact protection and outstanding energy return.
- Nike SB Skateboarding Kits [link ] : For skateboarding’s debut on this summer’s global stage, Nike SB will introduce kits on the forefront of sustainable design. Athletes representing Team USA, France and Brazil will compete in uniforms designed with 100% recycled polyester, pattern efficiency for minimal waste and bright, bold styling (crafted in collaboration with Dutch artist Parra) to celebrate each nation’s unique sport culture.
- Space Hippie [link ] : In addition to product developed for athletes participating in the Tokyo 2020 Games, Nike will launch this spring an exploratory footwear collection that redefines what’s possible with sustainable product design. Space Hippie is constructed by transforming scrap material from factory floors – what Nike’s design teams have called “space junk” – into a radical expression of circular design. Every detail of the Space Hippie capsule collection, from material choices to methods of make to packaging, was chosen with consideration for its environmental impact, adding up to Nike’s lowest carbon footprint footwear.
NIKE, Inc., based near Beaverton, Oregon, is the world’s leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @NIKE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005708/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
